Answers are grounded in this paper and cite their sources.
Demonstrates advancements in BACE inhibitor manufacturing for Alzheimer's disease, highlighting strategic approaches.
Alzheimer’s disease (AD) remains a critical unmet medical need that Eli Lilly and Company has been working to address for many years. This manuscript details the evolution of Lilly’s BACE inhibitor program, highlighting the iterative synthetic strategies that enabled the advancement of multiple clinical development candidates. The work underscores how strategic retrosynthetic analysis and process optimization facilitated the translation of intricate medicinal chemistry targets into robust manufacturing processes, ultimately supporting clinical development efforts in AD despite the inherent challenges and program terminations encountered along the way.
No takes yet. Share an insight, caveat, or question.
Frederick et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: